Pengnian Charles  Lin, Ph.D.
Pengnian Charles Lin, Ph.D.
Senior Investigator
Head, Vascular Biology Section

Center for Cancer Research
National Cancer Institute

Building 560, Room 12-89
Frederick, MD 21702-1201
301-228-4688

We seek to elucidate the mechanisms that govern vascular formation and homeostasis. Vascular networks form to satisfy the metabolic demands of tissue growth during development. When we reach adulthood, the vasculature becomes quiescent. However, disease conditions disturb this delicate balance and reactivate endothelium. What distinguishes physiological from pathological angiogenesis in diseases is an important question. It has significant implications for therapeutic interventions. We propose that inflammation distinguishes pathological from physiological angiogenesis. To this end, we tend to take an inflammatory angle to study angiogenesis. Understanding the interaction between inflammation and pathological angiogenesis allows us the possibility to preferentially target angiogenesis in disease conditions and spare normal blood vessels.

Areas of Expertise
1) Vascular biology 2) Tumor microenvironment 3) Inflammation 4) Cancer Biology 5) Angiogenesis .

Vascular biology plays a vital role in the progression of many debilitating diseases, including cancer, diabetes, and heart disease. Vascular disease is the most common cause of death and disability in Western societies. Understanding the vascular system is critical in the war against these diseases. Research in Dr. Lin's laboratory centers on the mechanisms that govern blood vessel formation (angiogenesis) and vascular homeostasis in cancer. Vascular networks form to satisfy the metabolic demands of tissue growth during development. When we reach adulthood, the vascular endothelium becomes quiescent. However, under disease conditions, this delicate balance is disturbed and endothelium is reactivated.

What distinguishes physiological angiogenesis during normal growth from pathological angiogenesis in diseases is an important question, which has major implications in therapeutic interventions. Dr. Lin's group believes the major difference is inflammation. Their working hypothesis is that tissue injury/insult leads to inflammation, which then triggers pathological angiogenesis. To this end, they are focusing on the interaction between inflammation and pathological angiogenesis, which offer the potential to preferentially target angiogenesis in disease conditions and spare normal blood vessels. Dr. Lin's group combines genetic and biochemical approaches, in vitro, three-dimensional organotypic culture and animal models as well as non-invasive imaging technology, to dissect the molecular mechanisms of angiogenesis and vascular homeostasis in cancer.

The current research focuses on three areas:

  1. Role of myeloid suppresser cells in regulation of the tumor microenvironment with a focus on angiogenesis and lymphangiogenesis
  2. Vascular integrity and endothelial-to-mesenchymal transformation (EMT) in tumor progression
  3. Exploring the genetic differences in vasculature between human and other species
Scientific Focus Areas:
Cancer Biology, Immunology, Stem Cell Biology
Selected Recent Publications
  1. Zhou W, Fong MY, Min Y, Somlo G, Liu L, Palomares MR, Yu Y, Chow A, O'Connor ST, Chin AR, Yen Y, Wang Y, Marcusson EG, Chu P, Wu J, Wu X, Li AX, Li Z, Gao H, Ren X, Boldin MP, Lin PC, Wang SE.
    Cancer Cell. 25: 501-15, 2014. [ Journal Article ]
  2. Schietinger A, Arina A, Liu RB, Wells S, Huang J, Engels B, Bindokas V, Bartkowiak T, Lee D, Herrmann A, Piston DW, Pittet MJ, Lin PC, Zal T, Schreiber H.
    Oncoimmunology. 2: e26677, 2013. [ Journal Article ]
  3. Qu P, Boelte KC, Lin PC.
    Immunol. Invest. 41: 562-80, 2012. [ Journal Article ]
  4. Sun J, Gao Y, Isaacs RJ, Boelte KC, Lin PC, Boczko EM, Li D.
    Anal. Chem. 84: 2017-24, 2012. [ Journal Article ]
  5. Gao Y, Majumdar D, Jovanovic B, Shaifer C, Lin PC, Zijlstra A, Webb DJ, Li D.
    Biomed Microdevices. 13: 539-48, 2011. [ Journal Article ]

Dr. P. Charles Lin received his Ph.D. in Cell and Molecular Biology (1988) at the Peking Union Medical College, Institute of Chinese Medical Sciences, Beijing, China. In 1992, he joined the Department of Medicine, Duke University Medical Center as a Research Associate. In 1999, Dr. Lin was appointed Assistant Professor at Vanderbilt University Medical Center. In 2005, he became Associate Professor with Tenure at the Department of Radiation Oncology, Department of Cancer Biology, and Department of Cell & Development Biology at Vanderbilt University School of Medicine. Dr. Lin established the Vascular Biology Section with the MCGP at the Center for Cancer Research in August, 2010.

Position Number of Positions Contact E-mail Contact Name Contact Phone
Postdoctoral Fellow 2

Linp3@mail.nih.gov

Charles Lin 301-846-6636
Name Position
Jaewoo Hong Postdoctoral Fellow (CRTA)
Jingyi Liu Postdoctoral Fellow (Visiting)
Lois McKennett Animal Technician (Contr)
Yongfen Min Ph.D. Research Fellow
Peng Qu Ph.D. Research Fellow
Lizhen Wang Ph.D. Postdoctoral Fellow (Visiting)
Todd Wuest Ph.D. Postdoctoral Fellow (CRTA)

Summary

We seek to elucidate the mechanisms that govern vascular formation and homeostasis. Vascular networks form to satisfy the metabolic demands of tissue growth during development. When we reach adulthood, the vasculature becomes quiescent. However, disease conditions disturb this delicate balance and reactivate endothelium. What distinguishes physiological from pathological angiogenesis in diseases is an important question. It has significant implications for therapeutic interventions. We propose that inflammation distinguishes pathological from physiological angiogenesis. To this end, we tend to take an inflammatory angle to study angiogenesis. Understanding the interaction between inflammation and pathological angiogenesis allows us the possibility to preferentially target angiogenesis in disease conditions and spare normal blood vessels.

Areas of Expertise
1) Vascular biology 2) Tumor microenvironment 3) Inflammation 4) Cancer Biology 5) Angiogenesis .

Research

Vascular biology plays a vital role in the progression of many debilitating diseases, including cancer, diabetes, and heart disease. Vascular disease is the most common cause of death and disability in Western societies. Understanding the vascular system is critical in the war against these diseases. Research in Dr. Lin's laboratory centers on the mechanisms that govern blood vessel formation (angiogenesis) and vascular homeostasis in cancer. Vascular networks form to satisfy the metabolic demands of tissue growth during development. When we reach adulthood, the vascular endothelium becomes quiescent. However, under disease conditions, this delicate balance is disturbed and endothelium is reactivated.

What distinguishes physiological angiogenesis during normal growth from pathological angiogenesis in diseases is an important question, which has major implications in therapeutic interventions. Dr. Lin's group believes the major difference is inflammation. Their working hypothesis is that tissue injury/insult leads to inflammation, which then triggers pathological angiogenesis. To this end, they are focusing on the interaction between inflammation and pathological angiogenesis, which offer the potential to preferentially target angiogenesis in disease conditions and spare normal blood vessels. Dr. Lin's group combines genetic and biochemical approaches, in vitro, three-dimensional organotypic culture and animal models as well as non-invasive imaging technology, to dissect the molecular mechanisms of angiogenesis and vascular homeostasis in cancer.

The current research focuses on three areas:

  1. Role of myeloid suppresser cells in regulation of the tumor microenvironment with a focus on angiogenesis and lymphangiogenesis
  2. Vascular integrity and endothelial-to-mesenchymal transformation (EMT) in tumor progression
  3. Exploring the genetic differences in vasculature between human and other species
Scientific Focus Areas:
Cancer Biology, Immunology, Stem Cell Biology

Publications

Selected Recent Publications
  1. Zhou W, Fong MY, Min Y, Somlo G, Liu L, Palomares MR, Yu Y, Chow A, O'Connor ST, Chin AR, Yen Y, Wang Y, Marcusson EG, Chu P, Wu J, Wu X, Li AX, Li Z, Gao H, Ren X, Boldin MP, Lin PC, Wang SE.
    Cancer Cell. 25: 501-15, 2014. [ Journal Article ]
  2. Schietinger A, Arina A, Liu RB, Wells S, Huang J, Engels B, Bindokas V, Bartkowiak T, Lee D, Herrmann A, Piston DW, Pittet MJ, Lin PC, Zal T, Schreiber H.
    Oncoimmunology. 2: e26677, 2013. [ Journal Article ]
  3. Qu P, Boelte KC, Lin PC.
    Immunol. Invest. 41: 562-80, 2012. [ Journal Article ]
  4. Sun J, Gao Y, Isaacs RJ, Boelte KC, Lin PC, Boczko EM, Li D.
    Anal. Chem. 84: 2017-24, 2012. [ Journal Article ]
  5. Gao Y, Majumdar D, Jovanovic B, Shaifer C, Lin PC, Zijlstra A, Webb DJ, Li D.
    Biomed Microdevices. 13: 539-48, 2011. [ Journal Article ]

Biography

Dr. P. Charles Lin received his Ph.D. in Cell and Molecular Biology (1988) at the Peking Union Medical College, Institute of Chinese Medical Sciences, Beijing, China. In 1992, he joined the Department of Medicine, Duke University Medical Center as a Research Associate. In 1999, Dr. Lin was appointed Assistant Professor at Vanderbilt University Medical Center. In 2005, he became Associate Professor with Tenure at the Department of Radiation Oncology, Department of Cancer Biology, and Department of Cell & Development Biology at Vanderbilt University School of Medicine. Dr. Lin established the Vascular Biology Section with the MCGP at the Center for Cancer Research in August, 2010.

Positions

Position Number of Positions Contact E-mail Contact Name Contact Phone
Postdoctoral Fellow 2

Linp3@mail.nih.gov

Charles Lin 301-846-6636

Team

Name Position
Jaewoo Hong Postdoctoral Fellow (CRTA)
Jingyi Liu Postdoctoral Fellow (Visiting)
Lois McKennett Animal Technician (Contr)
Yongfen Min Ph.D. Research Fellow
Peng Qu Ph.D. Research Fellow
Lizhen Wang Ph.D. Postdoctoral Fellow (Visiting)
Todd Wuest Ph.D. Postdoctoral Fellow (CRTA)